• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部晚期头颈部癌症女性患者的治疗不足。

Undertreatment of women with locoregionally advanced head and neck cancer.

机构信息

Department of Internal Medicine, Scripps Mercy, San Diego, California.

Division of Research, Kaiser Permanente, Oakland, California.

出版信息

Cancer. 2019 Sep 1;125(17):3033-3039. doi: 10.1002/cncr.32187. Epub 2019 May 15.

DOI:10.1002/cncr.32187
PMID:31090932
Abstract

BACKGROUND

It is difficult to predict whether a patient with head and neck cancer (HNC) is more likely to die of the cancer or another comorbidity. Competing event models can help to identify individual patients or groups of patients who may be undertreated or overtreated in clinical practice.

METHODS

Patients with HNC (n = 884), aged 18 to 85 years and diagnosed from 2000 to 2015 with stage II to IVB disease according to the seventh edition of the American Joint Committee on Cancer system, were identified. With a generalized competing event (GCE) model that controlled for age, sex, tumor site, surgical treatment, and Charlson Comorbidity Index (CCI), the association between these factors and the relative hazard for cancer mortality was determined. Logistic regression models were used to estimate the odds of receiving platinum-based chemoradiotherapy or a less intensive therapy, with adjustments made for age, sex, tumor site, CCI, stage, smoking, and alcohol abuse history.

RESULTS

Compared with men, women had an increased relative hazard ratio for death from HNC versus other causes, which was reported as an adjusted ω ratio comparing women with men (ω ratio, 1.95; 95% CI, 1.09-3.49), even though they were less likely to receive intensive chemoradiotherapy than men (adjusted odds ratio, 0.69; 95% CI, 0.48-0.99).

CONCLUSIONS

These findings indicate that women in this cohort may be undertreated in clinical practice and potentially miss the opportunity for their HNC to be aggressively treated. This study supports the use of GCE models to identify patients who are potentially undertreated and may also help to guide future research in health disparities.

摘要

背景

预测头颈部癌症(HNC)患者更有可能死于癌症还是其他合并症较为困难。竞争事件模型有助于识别出在临床实践中可能治疗不足或过度治疗的个体患者或患者群体。

方法

我们确定了 884 名年龄在 18 至 85 岁之间的 HNC 患者,这些患者根据第七版美国癌症联合委员会系统被诊断为 II 期至 IVB 期疾病。通过控制年龄、性别、肿瘤部位、手术治疗和 Charlson 合并症指数(CCI)的广义竞争事件(GCE)模型,确定了这些因素与癌症死亡率相对风险之间的关联。使用逻辑回归模型来估计接受铂类放化疗或不太强化治疗的可能性,并根据年龄、性别、肿瘤部位、CCI、分期、吸烟和酒精滥用史进行调整。

结果

与男性相比,女性因 HNC 以外的原因死亡的相对危险比更高,这是通过比较女性与男性的调整后 ω 比来报告的(ω 比,1.95;95%CI,1.09-3.49),尽管她们接受强化放化疗的可能性低于男性(调整后的比值比,0.69;95%CI,0.48-0.99)。

结论

这些发现表明,该队列中的女性在临床实践中可能治疗不足,可能错过了积极治疗 HNC 的机会。本研究支持使用 GCE 模型来识别潜在治疗不足的患者,也可能有助于指导未来在健康差异方面的研究。

相似文献

1
Undertreatment of women with locoregionally advanced head and neck cancer.局部晚期头颈部癌症女性患者的治疗不足。
Cancer. 2019 Sep 1;125(17):3033-3039. doi: 10.1002/cncr.32187. Epub 2019 May 15.
2
Selection of Head and Neck Cancer Patients for Intensive Therapy.头颈部癌症患者的强化治疗选择。
Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):157-166. doi: 10.1016/j.ijrobp.2019.09.011. Epub 2019 Sep 30.
3
Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.列线图预测局部晚期头颈部癌症强化治疗的获益。
Clin Cancer Res. 2019 Dec 1;25(23):7078-7088. doi: 10.1158/1078-0432.CCR-19-1832. Epub 2019 Aug 16.
4
Risk factors for competing non-cancer mortality after definitive treatment for advanced-stage head and neck cancer.晚期头颈部癌症根治性治疗后竞争非癌症死亡率的危险因素。
Oral Dis. 2018 Oct;24(7):1217-1225. doi: 10.1111/odi.12904. Epub 2018 Jun 28.
5
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.接受放化疗的局部晚期头颈癌患者的竞争性死亡原因和第二原发性肿瘤
Clin Cancer Res. 2004 Mar 15;10(6):1956-62. doi: 10.1158/1078-0432.ccr-03-1077.
6
Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.西妥昔单抗与铂类同步放化疗用于局部晚期头颈癌的根治性治疗
Head Neck. 2015 Mar;37(3):386-92. doi: 10.1002/hed.23609. Epub 2014 Apr 16.
7
Race and competing mortality in advanced head and neck cancer.种族与晚期头颈部癌症的竞争死亡率。
Oral Oncol. 2014 Jan;50(1):40-4. doi: 10.1016/j.oraloncology.2013.09.012. Epub 2013 Oct 14.
8
Comorbidity in head and neck cancer: Is it associated with therapeutic delay, post-treatment mortality and survival in a population-based study?头颈部癌症的合并症:在基于人群的研究中,它与治疗延误、治疗后死亡率和生存有关吗?
Oral Oncol. 2020 Mar;102:104561. doi: 10.1016/j.oraloncology.2019.104561. Epub 2020 Jan 7.
9
Predictors of competing mortality in advanced head and neck cancer.晚期头颈部癌症竞争死亡率的预测因素。
J Clin Oncol. 2010 Jan 1;28(1):15-20. doi: 10.1200/JCO.2008.20.9288. Epub 2009 Nov 23.
10
Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.根治性放化疗后替吉奥辅助化疗治疗局部晚期头颈部鳞状细胞癌患者:ACTS-HNC 研究的再分析。
PLoS One. 2018 Jun 8;13(6):e0198391. doi: 10.1371/journal.pone.0198391. eCollection 2018.

引用本文的文献

1
Exploring gender-specific prognostic factors and survival outcomes in oral squamous cell carcinoma: Insights from a Taiwanese cohort.探索口腔鳞状细胞癌的性别特异性预后因素和生存结果:来自台湾队列的见解。
J Dent Sci. 2025 Jul;20(3):1832-1842. doi: 10.1016/j.jds.2025.04.026. Epub 2025 May 9.
2
Sex differences in prognostic factors and genomic variations in oral squamous cell carcinoma: A 5-year retrospective study.口腔鳞状细胞癌预后因素和基因组变异中的性别差异:一项5年回顾性研究。
J Dent Sci. 2025 Apr;20(2):1086-1094. doi: 10.1016/j.jds.2024.12.014. Epub 2025 Jan 3.
3
Sex Differences in Head and Neck Carcinoma - A Retrospective Study on 1115 Head and Neck Carcinoma Patients in Austria.
头颈癌中的性别差异——奥地利1115名头颈癌患者的回顾性研究
J Otolaryngol Head Neck Surg. 2025 Jan-Dec;54:19160216251318238. doi: 10.1177/19160216251318238. Epub 2025 Apr 12.
4
Sex differences in laryngeal cancer treated with COtransoral laser microsurgery: a case-control study.经口二氧化碳激光显微手术治疗喉癌的性别差异:一项病例对照研究。
Eur Arch Otorhinolaryngol. 2025 May;282(5):2493-2505. doi: 10.1007/s00405-025-09315-x. Epub 2025 Mar 14.
5
Laryngeal Cancer in Women: Unveiling Gender-Specific Risk Factors, Treatment Challenges, and Survival Disparities.女性喉癌:揭示特定性别的风险因素、治疗挑战及生存差异
Curr Oncol. 2024 Dec 29;32(1):19. doi: 10.3390/curroncol32010019.
6
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials.接受化疗和放疗的头颈癌患者的治疗相关死亡率:已发表试验的荟萃分析结果
Ther Adv Med Oncol. 2025 Jan 10;17:17588359241288251. doi: 10.1177/17588359241288251. eCollection 2025.
7
Sex-related differences in oncological surgery and postoperative outcomes: comprehensive, nationwide study in France.法国全国性的综合研究:肿瘤外科和术后结局的性别差异。
Br J Surg. 2024 Aug 2;111(8). doi: 10.1093/bjs/znae179.
8
Promoter DNA methylation patterns in oral, laryngeal and oropharyngeal anatomical regions are associated with tumor differentiation, nodal involvement and survival.口腔、喉和口咽解剖区域的启动子DNA甲基化模式与肿瘤分化、淋巴结受累及生存情况相关。
Oncol Lett. 2024 Jan 8;27(3):89. doi: 10.3892/ol.2024.14223. eCollection 2024 Mar.
9
Effects of gender and socio-environmental factors on health-care access in oncology: a comprehensive, nationwide study in France.性别和社会环境因素对肿瘤医疗服务可及性的影响:法国一项全国性综合研究
EClinicalMedicine. 2023 Nov 1;65:102298. doi: 10.1016/j.eclinm.2023.102298. eCollection 2023 Nov.
10
Immunotherapy and Hypofractionated Radiotherapy in Older Patients with Locally Advanced Cutaneous Squamous-Cell Carcinoma of the Head and Neck: A Proposed Paradigm by the International Geriatric Radiotherapy Group.老年局部晚期头颈部皮肤鳞状细胞癌患者的免疫治疗与低分割放疗:国际老年放疗小组提出的范例
Cancers (Basel). 2023 Oct 13;15(20):4981. doi: 10.3390/cancers15204981.